Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial.

@article{Ritchie2003MetalproteinAW,
  title={Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial.},
  author={Craig William Ritchie and Ashley I. Bush and Andrew Mackinnon and Steve Macfarlane and Maree Mastwyk and Lachlan MacGregor and Lyn Kiers and Robert Cherny and Qiao-xin Li and Amanda Tammer and Darryl P Carrington and Christine Mavros and Irene Volitakis and Michel E Xilinas and David Ames and Stephen Davis and Konrad Beyreuther and Rudolph E. Tanzi and Colin L. Masters},
  journal={Archives of neurology},
  year={2003},
  volume={60 12},
  pages={1685-91}
}
BACKGROUND Alzheimer disease (AD) may be caused by the toxic accumulation of beta-amyloid (Abeta). OBJECTIVE To test this theory, we developed a clinical intervention using clioquinol, a metal-protein-attenuating compound (MPAC) that inhibits zinc and copper ions from binding to Abeta, thereby promoting Abeta dissolution and diminishing its toxic properties. METHODS A pilot phase 2 clinical trial in patients with moderately severe Alzheimer disease. RESULTS Thirty-six subjects were… CONTINUE READING
Highly Influential
This paper has highly influenced a number of papers. REVIEW HIGHLY INFLUENTIAL CITATIONS